



ciclosporin 1mg/mL eye drops, solution in multi-dose container (Vevizye®)

Thea Pharmaceuticals Limited

23 October 2025 (*Issued 05 December 2025*)

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

ciclosporin (Vevizye®) is accepted for restricted use within NHSScotland.

Indication under review: treatment of moderate to severe dry eye disease (keratoconjunctivitis sicca) in adult patients, which has not improved despite treatment with tear substitutes.

SMC restriction: severe keratitis in adult patients with dry eye disease.

Vevizye® is a new formulation of ciclosporin eye drops, with limited net budget impact.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 22 October 2025.

Vice Chair
Scottish Medicines Consortium

Published 19 January 2026